Koninklijke Philips N.V. (0LNG.IL)
| Previous close | 18.82 |
| Open | 18.74 |
| Bid | 17.97 x 0 |
| Ask | 19.84 x 0 |
| Day's range | 18.57 - 19.01 |
| 52-week range | 16.12 - 22.19 |
| Volume | |
| Avg. volume | 1,010,982 |
| Market cap | 18.958B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 May 2023 |
| 1y target est | N/A |
- Zacks
Philips (PHG) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
- Reuters
Philips shares rise on final US deal on sleep apnea machines
Philips said it had reached what is known as a consent decree that spells out the improvements it needs to make at its Respironics plants in the United States. In January, Philips said the costs of the consent decree led to a provision of 363 million euros in the fourth quarter of 2023, and were expected to be about 1% of total revenue in 2024. The agreement followed the recall of millions of breathing devices and ventilators used to treat sleep apnea in 2021, because of concerns that foam used to reduce noise from the devices could degrade and become toxic, carrying potential cancer risks.
- Reuters
US federal court orders Philips to restrict production of sleep apnea devices
(Reuters) -A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.
